Home > Search Results: Bang, Yung-Jue
  Search Tips
Advanced Search
Search collections:
Sort by: Display results: Output format:
Results overview: Found 4 records in 0.02 seconds.
Articles, 4 records found
Articles 4 records found  
1.
11 p, 726.2 KB Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061 / Van Cutsem, Eric (University Hospitals Gasthuisberg (Leuven, Bélgica)) ; Amonkar, Mayur (Merck & Co., Inc.. Center for Observational and Real World Evidence) ; Fuchs, Charles S. (Yale School of Medicine. Yale Cancer Center) ; Alsina, Maria (Vall d'Hebron Institut d'Oncologia) ; Özgüroğlu, Mustafa (Istanbul University-Cerrahpaşa. Department of Internal Medicine, Medical Oncology, and Clinical Trial Unit) ; Bang, Yung-Jue (Seoul National University College of Medicine. Department of Internal Medicine) ; Chung, Hyun Cheol (Yonsei University College of Medicine. Department of Medical Oncology) ; Muro, Kei (Aichi Cancer Center Hospital) ; Goekkurt, Eray (University Cancer Center Hamburg. North-German Trial Center for Innovative Oncology) ; Benson, Al B. (Northwestern University. Robert H. Lurie Comprehensive Cancer Center) ; Sun, Weijing (University of Kansas. Department of Internal Medicine and Medical Oncology) ; Wainberg, Zev A. (David Geffen School of Medicine at UCLA. Department of Medicine and Hematology and Oncology) ; Norquist, Josephine M. (Merck & Co., Inc.. Center for Observational and Real World Evidence) ; Chen, Xinqun (Merck & Co., Inc.. Department of Medical Oncology) ; Shih, Chie-Schin (Merck & Co., Inc.. Department of Medical Oncology) ; Shitara, Kohei (National Cancer Center Hospital. Department of Gastrointestinal Oncology) ; Universitat Autònoma de Barcelona
In the primary analysis population (i. e. , PD-L1 combined positive score [CPS] ≥ 1) of the phase 3 KEYNOTE-061 study (NCT02370498), pembrolizumab did not significantly prolong overall survival or progression-free survival. [...]
2021 - 10.1007/s10120-021-01200-w
Gastric Cancer, Vol. 24 (august 2021) , p. 1330-1340  
Detailed record - Creative Commons
2.
11 p, 588.4 KB Quality of life with first-line pembrolizumab for PD-L1-positive advanced gastric/gastroesophageal junction adenocarcinoma : results from the randomised phase III KEYNOTE-062 study / Van Cutsem, E. (University Hospitals Gasthuisberg (Leuven, Bélgica)) ; Valderrama, A. (Center for Observational and Real-World Evidence, Merck) ; Bang, Yung-Jue (Seoul National University College of Medicine) ; Fuchs, C. S. (Yale University Cancer Center) ; Shitara, Kohei (National Cancer Center Hospital East, Kashiwa, Japan) ; Janjigian, Y. Y. (Memorial Sloan Kettering Cancer Center) ; Qin, S. (PLA Cancer Centre of Nanjing Bayi Hospital) ; Larson, T. G. (Minnesota Oncology Hematology) ; Shankaran, V. (Seattle Cancer Care Alliance) ; Stein, S. (Yale University Cancer Center) ; Norquist, J. M. (Center for Observational and Real-World Evidence, Merck) ; Kher, U. (Department of Medical Oncology, Merck) ; Shah, S. (Department of Medical Oncology, Merck) ; Alsina, Maria (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Universitat Autònoma de Barcelona
In the randomised phase III KEYNOTE-062 study, pembrolizumab was non-inferior to chemotherapy for overall survival in patients with programmed death-ligand 1 (PD-L1)-positive [combined positive score (CPS) ≥1] advanced gastric/gastroesophageal junction (GEJ) cancer. [...]
2021 - 10.1016/j.esmoop.2021.100189
ESMO open, Vol. 6 (august 2021)  
Detailed record - Creative Commons
3.
12 p, 435.5 KB Phase 1 study of capmatinib in MET-positive solid tumor patients : Dose escalation and expansion of selected cohorts / Bang, Yung-Jue (Seoul National University College of Medicine) ; Su, Wu-Chou (National Cheng Kung University Hospital) ; Schuler, Martin (University Duisburg-Essen and German Cancer Consortium (DKTK)) ; Nam, Do-Hyun (Samsung Medical Center) ; Lim, Wan Teck (National Cancer Centre) ; Bauer, Todd M. (PLLC) ; Azaro, Analía (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ; Poon, Ronnie Tung Ping (Queen Mary Hospital) ; Hong, David (University of Texas/MD Anderson Cancer Center) ; Lin, Chia-Chi (National Taiwan University Hospital (Taipei, Taiwan)) ; Akimov, Mikhail (Novartis Pharma AG) ; Ghebremariam, Samson (Novartis Pharmaceuticals Corporation) ; Zhao, Sylvia (China Novartis Institutes for Biomedical Research) ; Giovannini, Monica (Novartis Pharmaceuticals Corporation) ; Ma, Brigette (The Chinese University of Hong Kong)
Capmatinib is an oral, ATP-competitive, and highly potent, type 1b MET inhibitor. Herein, we report phase 1 dose-escalation results for capmatinib in advanced MET-positive solid tumor patients and dose expansion in advanced non-lung tumors. [...]
2019 - 10.1111/cas.14254
Cancer Science, Vol. 111 (december 2019) , p. 536-547  
Detailed record - Creative Commons
4.
11 p, 542.8 KB A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer / Reynolds, Kerry Lynn ; Bedard, Philippe L (Toronto, ON Canada) ; Lee, Se-Hoon (Seoul, Republic of Korea) ; Lin, Chia-Chi (Taipei, Taiwan) ; Tabernero, Josep (Hospital Universitari Vall d'Hebron) ; Alsina, Maria (Hospital Universitari Vall d'Hebron) ; Cohen, Ezra (La Jolla, CA USA) ; Baselga Torres, Josep, 1959-2021, (New York, NY USA) ; Blumenschein, George (Houston, TX USA) ; Graham, Donna M. (Toronto, ON Canada) ; Garrido-Laguna, Ignacio (Salt Lake City, UT USA) ; Juric, Dejan (Fruit Street, Boston, MA 02114 USA) ; Sharma, Sunil (Salt Lake City, UT USA) ; Salgia, Ravi (Duarte, CA USA) ; Seroutou, Abdelkader (Basel, Switzerland) ; Tian, Xianbin (East Hanover, NJ USA) ; Fernandez, Rose (East Hanover, NJ USA) ; Morozov, Alex (New York, NY USA) ; Sheng, Qing (Cambridge, MA USA) ; Ramkumar, Thiruvamoor (East Hanover, NJ USA) ; Zubel, Angela (Basel, Switzerland) ; Bang, Yung-Jue (Seoul, Republic of Korea) ; Universitat Autònoma de Barcelona
Human epidermal growth factor receptor 3 (HER3) is important in maintaining epidermal growth factor receptor-driven cancers and mediating resistance to targeted therapy. A phase I study of anti-HER3 monoclonal antibody LJM716 was conducted with the primary objective to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE), and dosing schedule. [...]
2017 - 10.1186/s12885-017-3641-6
BMC Cancer, Vol. 17 (september 2017)  
Detailed record - Creative Commons

See also: similar author names
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.
UAB Digital Repository of Documents :: Search :: Submit :: Personalize :: Help
Powered by Invenio v1.1.6
Maintained by ddd.bib@uab.cat  :: Metadata license:
Working with